Shots:
- Hengrui Pharma has entered into a license agreement with Novo for HRS-1596, a P-I-ready GLP-1 receptor & gastric inhibitory polypeptide receptor dual agonist, with potential for QW oral dosing
- As per the deal, Novo will obtain exclusive rights to develop, manufacture & commercialize HRS-1596 globally, excl. Mainland China, the Hong Kong SAR, the Macao SAR & Taiwan Region
- Hengrui will receive ~$2.6B in development, regulatory & commercial milestones payments, incl. a $300M upfront payment, plus net sales-based royalties; closing is expected in Q4’26
Ref: PRnewswire | Image: Hengrui & Novo | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
